#United States #San Francisco #Achieve Life Sciences #cytisinicline #nicotine dependence

Achieve Life Sciences to Host Meetings During J.P. Morgan Healthcare Conference Week

Achieve Life Sciences, Inc., a prominent name in late-stage specialty pharmaceuticals, is set to hold a series of important meetings during the upcoming 44th Annual J.P. Morgan Healthcare Conference, scheduled from January 12 to 15, 2026, in San Francisco. This event is a significant gathering in the healthcare sector, offering excellent networking opportunities and a platform for industry leaders to discuss breakthroughs and advancements in healthcare.

The CEO of Achieve Life Sciences, Rick Stewart, alongside other key management personnel, will be present to provide insights into their late-stage program centered around cytisinicline. This medication is under development as a treatment for nicotine dependence, aiming to help individuals quit smoking and vaping. As part of the meetings, Achieve Life Sciences plans to discuss their strategic plans for the coming year, including clinical developments and commercialization efforts.

The focus of Achieve is on addressing the urgent global health crisis posed by smoking and nicotine addiction. In fact, statistics indicate that there are roughly 29 million adult smokers in the United States, and tobacco use is the leading cause of preventable fatalities worldwide. With approximately 8 million death cases linked to tobacco every year, the need for effective cessation aids has never been more critical.

In June 2025, Achieve submitted a New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA), which has been accepted for review. The FDA has established a Prescription Drug User Fee Act (PDUFA) target date of June 20, 2026, for this application, which is based on the outcomes of two successful Phase 3 studies along with an open-label safety study. The findings underscore the potential of cytisinicline as a viable treatment for nicotine dependence in adults who wish to quit smoking.

Further expansion of cytisinicline’s application is indicated as the company has also completed a Phase 2 study focusing on vaping cessation and has held a positive end-of-Phase 2 meeting with the FDA regarding this indication. The rise of e-cigarette use has added complexity to the smoking epidemic, making cytisinicline’s development for this specific audience of paramount importance, especially since no FDA-approved treatments currently exist for nicotine e-cigarette cessation.

Cytisinicline is a plant-derived alkaloid that operates by strongly binding to nicotinic acetylcholine receptors in the brain. This interaction is believed to alleviate the intensity of nicotine cravings and mitigate the gratification associated with the consumption of nicotine products. The drug is still investigational, meaning it has not yet received FDA approval for any use in the United States, yet it holds promise as a future treatment avenue.

Achieve Life Sciences encourages those interested in scheduling a one-on-one meeting with company representatives during the conference to reach out through their Investor Relations contact at [provide email contact]. Such opportunities will allow stakeholders to delve deeper into the strategic progress and future plans of Achieve Life Sciences.

As the healthcare landscape continues to evolve, Achieve Life Sciences remains committed to addressing the nicotine dependence epidemic across the globe through its innovative approach and dedicated focus on cytisinicline. The attendance at the J.P. Morgan Healthcare Conference marks an essential part of their outreach and commitment to stakeholders looking to collaborate in combating this public health challenge.